Extensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network. Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to... Read More

Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets. Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce the formal grant of patents... Read More

Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strategic Expression of Interest (EOI) agreement with SAMA CONSULTING SARL ("SAMA CONSULTING")... Read More

Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announces today the completion of a strategic laboratory equipment leasing agreement,... Read More

Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, today announced a summary of its fiscal year 2025 highlights and key milestones for 2025 - 2026. The Company's annual financial filings are available on the SEDAR+ website at www.sedarplus.ca and on... Read More

Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of a significant study exploring... Read More

Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the publication of a... Read More

Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc . (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) (" BioMark " or the " Company "), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the successful closing of its previously announced oversubscribed non-brokered private placement. The closing of the second and final tranche builds upon the momentum of the previously announced... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that it has arranged and completed financing for the initial tranche of its non-brokered private placement (the "Private Placement"). Demonstrating strong investor confidence in BioMark's vision and... Read More

BioMark is pioneering liquid biopsy solutions for challenging conditions and championing equity in diagnosis Vancouver, British Columbia--(Newsfile Corp. - February 28, 2025) - BioMark Diagnostics Inc. ( CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, proudly joins today the global community in recognizing Rare Disease Day 2025. This annual... Read More

BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast Cancer Vancouver, British Columbia--(Newsfile Corp. - December 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leader in liquid biopsy tests for early cancer detection, announced a significant advancement in its breast cancer diagnostic capabilities. A groundbreaking study published in the International Journal... Read More

BioMark Strengthens Liquid Biopsy Platform for Breast Cancer Detection Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced significant progress in its breast cancer program. The Company's liquid biopsy platform, leveraging metabolomics and machine... Read More

BioMark's Liquid Biopsy Technology Offers Promise for NEN Diagnosis Vancouver, British Columbia--(Newsfile Corp. - September 24, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is excited to announce that its latest work, has been published in Cancers, titled "Metabolic Profiling of Pulmonary Neuroendocrine Neoplasms." This paper... Read More

Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer Screening Vancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce today the successful completion of a significant clinical trial in collaboration with the Institut Universitaire... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that Chief Executive Officer Rashid Bux and Chief Scientific Officer Jean-François Haince will participate in the upcoming H.C. Wainwright 26 th Annual Global Investment Conference in New York. The... Read More

The new patent granted by the USPTO strengthens and expands BioMark's global IP portfolio in liquid biopsy, enhancing cancer management solutions. Vancouver, British Columbia--(Newsfile Corp. - July 31, 2024) - BioMark Diagnostics Inc. , (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to... Read More

Vancouver, British Columbia--(Newsfile Corp. - July 15, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long time collaborators at the University of Manitoba Therapeutics will be presenting this week compelling new research findings on... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that the Company intends to amend the terms of 5,062,000 the non-broker warrants (the "Warrants") issued to a private placement financing that closed on... Read More

The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia--(Newsfile Corp. - April 9, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today it has received non-dilutive... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic partnership to develop better diagnostic tools... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced-stage liquid biopsy company with a focus on hard-to-detect and treat cancers is pleased to announce that Mrs. Theresa Peterson as a new member of BioMark's Advisory team. Mr. Rashid Ahmed Bux, CEO and President of BioMark Diagnostics says: "We are extremely proud and... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. The financing round included a... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results from the second quarter ended September 30, 2023. The Company also announces that it intends to extend the warrant exercise term in a... Read More

Dr. W. Randolph Ford, Ph.D., will be joining BioMark's Advisory team to support Artificial Intelligence and Machine Learning capabilities. Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the appointment of Dr.... Read More

Vancouver, British Columbia and Quebec City, Quebec--(Newsfile Corp. - November 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid biopsy company focusing on metabolomics for the early diagnosis of hard to detect and treat cancers is pleased to announce today that its wholly owned laboratory subsidiary, BioMark Diagnostic Solutions Inc ("BDS"), has been awarded... Read More

Analyses from a retrospective study of early breast cancer metabolomics panel further demonstrate the diagnostic power of BioMark's liquid biopsy platform beyond early lung cancer detection. Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid biopsy company focusing on metabolomics for the early diagnosis of hard to... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that Vice Admiral Kevin Cosgriff will be joining BioMark's Advisory team to support its innovation and investment strategy. Mr. Rashid Ahmed Bux, CEO and President... Read More

New family of patent granted by Japanese Patent Office enhances BioMark's global intellectual property position in lung cancer detection using urine as a convenient biological sample medium. Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is... Read More

Vancouver, British Columbia--(Newsfile Corp. - July 25, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard-to-detect and treat cancers issued a statement today commenting on the recent market activity. The Company is unaware of any material change in its operations that would account for the recent increase in market activity and... Read More

BioMark's blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting. Vancouver, British Columbia--(Newsfile Corp. - June 5, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that its latest leading-edge research was... Read More

The new family of patent granted by USPTO strengthens BioMark's global intellectual property position in liquid biopsy and early cancer detection Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the U.S. Patent and... Read More

New analyses from a large retrospective validation study of early lung cancer metabolomics panel, underscoring strength of BioMark's liquid biopsy platform, to be presented. Vancouver, British Columbia--(Newsfile Corp. - May 3, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 16, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that novel liquid biopsy data presented this week suggests that Pulmonary Neuroendocrine Tumors (NETs) are reprogramming their metabolism as reflected by the presence of a... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December 31, 2022, as well as outlook for 2023. Business Update Highlights "We are excited to share our Q3 results which... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that its Quebec-based subsidiary, BioMark Diagnostic Solutions Inc ("BDS"), is receiving advisory services and non-dilutive funding of up to CAD... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical... Read More

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") (an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the "Warrants") issued in relation to a private placement financing that closed on December 13, 2019 on a continuing effort to improve corporate value for its... Read More